A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma

Clinical Genitourinary Cancer
David S HongLeonard J Appleman

Abstract

Trebananib, an investigational peptibody, binds to angiopoietin 1 and 2, thereby blocking their interaction with Tie2. This open-label phase I study examined trebananib 3 mg/kg or 10 mg/kg intravenous (I.V.) once weekly plus sorafenib 400 mg twice per day or sunitinib 50 mg once per day in advanced RCC. Primary end points were adverse event incidence and pharmacokinetics. Thirty-seven patients were enrolled. During trebananib plus sorafenib administration (n = 17), the most common treatment-related adverse events (TRAEs) included rash (n = 12; 71%), diarrhea (n = 12; 71%), hypertension (n = 11; 65%), and fatigue (n = 11; 65%); grade ≥ 3 TRAEs (n = 7; 41%); and 2 patients (12%) had peripheral edema. During trebananib plus sunitinib administration (n = 19), the most common TRAEs included diarrhea (n = 14; 74%), fatigue (n = 13; 68%), hypertension (n = 11; 58%), and decreased appetite (n = 11; 58%); grade ≥ 3 TRAEs (n = 13; 68%); and 8 (42%) patients had peripheral edema. Trebananib did not appear to alter the pharmacokinetics of sorafenib or sunitinib. No patient developed anti-trebananib antibodies. Objective response rates were 29% (trebananib plus sorafenib) and 53% (trebananib plus sunitinib). The toxicities of trebananib 3 m...Continue Reading

References

Dec 13, 2002·International Journal of Cancer. Journal International Du Cancer·Christian SfiligoiMichele De Bortoli
Mar 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laura Q M Chow, S Gail Eckhardt
Mar 31, 2007·Nature Reviews. Drug Discovery·Judah Folkman
Aug 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I RiniDaniel J George
Feb 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Darren R FeldmanRobert J Motzer
Apr 30, 2009·Cancer·Jeffrey Sosman, Igor Puzanov
Jun 3, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerRobert A Figlin
Jun 24, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roy S HerbstLee S Rosen
Aug 13, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John M L EbosRobert S Kerbel
Sep 10, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Samuel E DeprimoGeorge D Demetri
Mar 2, 2010·Journal of Immunological Methods·Zhandong D ZhongNarendra Chirmule
Aug 27, 2010·The Journal of Clinical Endocrinology and Metabolism·Michael B BassScott D Patterson
Sep 29, 2011·International Journal of Cancer. Journal International Du Cancer·Astrid A M van der VeldtEpie Boven
Dec 21, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Beth Y KarlanIgnace B Vergote

❮ Previous
Next ❯

Citations

May 20, 2015·Expert Opinion on Emerging Drugs·Roberto IacovelliBernard Escudier
Jun 3, 2015·Cancer Chemotherapy and Pharmacology·Benjamin WuYu-Nien Sun
Sep 24, 2014·Drug Discovery Today·Djoeke de WitNielka P van Erp
Dec 15, 2016·Expert Review of Anticancer Therapy·Elise NassifStéphane Oudard
Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael B AtkinsAlain Ravaud
Nov 10, 2015·Journal of the National Cancer Institute·Benjamin CarlisleJonathan Kimmelman
Feb 27, 2019·Current Oncology Reports·Jessica GillenKathleen Moore
Oct 16, 2016·Journal of Neurosurgery·Eugene J VaiosJorg Dietrich
Sep 27, 2015·Clinical Chemistry·Xuemei ZhaoOmar F Laterza
Nov 30, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daniela F Quail, Johanna A Joyce
Mar 21, 2021·European Journal of Pharmacology·Digna Parmar, Madhavi Apte

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.